Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.70 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.70 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.70 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.56 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.56 |
| ▸ | AMD1 | P17707 | 5/20 | 0.56 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.53 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
| ▸ | RBBP5 | Q15291 | 1/20 | 0.47 |
| ▸ | DPY30 | Q9C005 | 1/20 | 0.47 |
| ▸ | ASH2L | Q9UBL3 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | AHCY | P23526 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17153318 | 1.00 | PI4KA (0.70) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL954367 | 0.94 | PI4KA (0.68) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| Water SCHEMBL10663829 | 0.94 | PI4KA (0.67) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9970637 | 0.94 | PI4KA (0.67) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL15395675 | 0.94 | PI4KA (0.67) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL954215 | 0.91 | PI4KA (0.75) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL12915019 | 0.91 | PI4KA (0.75) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9970711 | 0.91 | PI4KA (0.75) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL15395676 | 0.91 | PI4KA (0.68) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9970632 | 0.90 | PI4KA (0.67) | PI4KAPI4K2BPI4K2API4KBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-05-18 | — | — | US | disclosed |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-05-18 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-9446064-B2 | Combination therapy for treating cancer | Epizyme, Inc. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446064-B2 | Combination therapy for treating cancer | Epizyme, Inc. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-20160045531-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2016-02-18 | — | — | US | disclosed |
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140323421-A1 | Combination Therapy for Treating Cancer | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323421-A1 | Combination Therapy for Treating Cancer | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| WO-2014153001-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014100662-A1 | DOT1 L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014026198-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012082436-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | PI4KA 3239/4885PI4K2B 3276/4885PI4K2A 3234/4885 |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | PI4KA 3239/4885PI4K2B 3276/4885PI4K2A 3234/4885 |
| US-20140323421-A1 | Combination Therapy for Treating Cancer | DOT1L, ASH1L, CARM1 | PI4KA 1540/4885PI4K2B 1677/4885PI4K2A 1640/4885 |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | PI4KA 1844/4885PI4K2B 1901/4885PI4K2A 1942/4885 |
| US-20160045531-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | PI4KA 1540/4885PI4K2B 1677/4885PI4K2A 1640/4885 |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | PI4KA 1844/4885PI4K2B 1901/4885PI4K2A 1942/4885 |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | PI4KA 3239/4885PI4K2B 3276/4885PI4K2A 3234/4885 |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | PI4KA 1540/4885PI4K2B 1677/4885PI4K2A 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.